IPG Photonics (IPGP) investor relations material

Executive summary

• Q3 revenue was $287.5M, up 14.6% YoY and 3% sequentially, marking a fourth consecutive quarter of double-digit YoY growth; results exceeded the midpoint of guidance.

• Strength in welding, additive manufacturing, semiconductor and defense applications lifted both segments; adjusted EBITDA was $51.5M and adjusted EPS was $0.61.

• Orders remained strong, with book-to-bill of ~1.

Financial highlights

• Q3 GAAP gross margin was 40.7%, versus 39.5% a year earlier; adjusted gross margin was 41.0%.

• GAAP operating income was $20.8M versus $7.9M, net income was $20.3M versus $7.5M, and diluted EPS was $0.47 versus $0.18.

• Adjusted operating income was $26.5M versus $12.4M; adjusted net income was $26.3M versus $14.8M; adjusted EBITDA was $51.5M versus $37.0M; adjusted EPS was $0.61 versus $0.35.

• 9M revenue increased 14.0% to $831.6M; net income was $27.1M versus $17.8M, including Belarus impairment and litigation settlement costs.

Outlook and guidance

• Q4 2026 guidance: revenue $265M–$295M, adjusted gross margin 37%–40%, adjusted operating expenses $91M–$94M, adjusted EPS $0.30–$0.60 and adjusted EBITDA $33M–$50M.

• Guidance assumes no Lumibird Medical contribution or meaningful tariff-refund benefit; diluted shares are ~43M.

• Management expects modest OpEx increases for growth investments; excluding the German facility investment, ongoing CapEx is expected to be ~5% of revenue.

• China battery capacity additions are moderating after several strong quarters; near-term effects are reflected in guidance, while longer-term capacity growth remains an opportunity.

• Lumibird Medical is expected to close in Q4 2026, subject to conditions and approvals; consideration is €300M plus up to €50M in contingent earn-outs.